Contract Research, Development and Production Institutions (CRDMO)TEDE Pharmaceuticals (03880.HK)Announcement of IPO in Hong Kong, Plans to Sell 16.8 Million Shares Worldwide, Hong Kong Development to Sell 10% (Approx. 1.68 Million Shares), International Sales Share 90% (15.12 Million Shares), Selling Price Per Share 28.4 to 630.630.USD, the maximum investment is about 0.514 trillion, and 100 shares per unit sold, and the entry fee is approximately 3,090.85 USD. The tender offer period from today (20) to Tuesday (25) is expected to be attached to June 30 and will be appointed as co-guarantors by Morgan Stanley and CITIC SEC.
Ted Pharma's IPO will introduce Microlight Ventures (01093.HK) and former Tencent (00700.HK) executive Wu, as cornerstone investors, to subscribe for $5 million each.
At the average IPO price of $29.5 per share, the IPO's net capitalization is approximately $0.411 billion, of which approximately 76.4% will be used primarily for construction of facilities in the United States and China, approximately 4.1% will be used to increase production capacity in China, approximately 9.5% will be used to expand the European sales network, and the remaining 10% will be used as working capital.
